MMSI Merit Medical Systems Inc.

Merit Medical Expands Embolics Portfolio with New Siege™ Vascular Plug and Bearing nsPVA Express™ Prefilled Syringe

Merit Medical Expands Embolics Portfolio with New Siege™ Vascular Plug and Bearing nsPVA Express™ Prefilled Syringe

  • New products broaden Merit’s leadership in embolotherapy.

  • Full portfolio will be exhibited at the 18th Annual GEST Meeting May 16-19 in New York City.

SOUTH JORDAN, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced US Food and Drug Administration (FDA) 510(k) clearance for its Siege Vascular Plug. Merit also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia.

The latest additions to Merit’s Embolics portfolio, Siege Vascular Plug and Bearing nsPVA Express, complement a comprehensive offering of microsphere, particle, and gelatin foam products supported by a range of microcatheters, guide wires, and other enabling devices.

Embolization is a minimally invasive procedure where physicians implant devices or materials to occlude blood vessels or abnormal vascular channels. It may be used to stop bleeding or to block the flow of blood to a tumor or abnormal area of tissue. Embolization has made remarkable advances in recent years, becoming a widely adopted treatment option.

The Siege Vascular Plug has a highly deliverable, recapturable design that enables precise placement. The nitinol self-expanding plug achieves vessel occlusion within 1.3 minutes.Available in three sizes, Siege treats peripheral arteries 1.5 mm to 6.0 mm in diameter. All sizes of the Siege Vascular Plug are delivered with a microcatheter.

“The Siege Vascular Plug will be a valuable addition to my clinical practice. A plug with rapid occlusion, precise placement, and microcatheter compatibility is important to me,” said Gary Siskin, MD, Professor and Chairman of the Radiology Department at Albany Medical Center in Albany, NY, and paid consultant of Merit.

The newly launched Bearing nsPVA Express is a 20-mL, vacuum-sealed syringe prefilled with Merit-manufactured Bearing nsPVA® Embolization Particles. Bearing nsPVA Embolization Particles are small, irregularly shaped, biocompatible, hydrophilic, and nonresorbable particles available in multiple sizes (45-1180 µm). The preloaded syringe offers convenience and ease of use that can save clinicians’ time and minimize product waste. In hands-on testing, 100% of clinicians found the Bearing nsPVA Express to be easily incorporated into a procedure, and 75% said it was easier to use than the vial product.1

“Bearing nsPVA Express streamlines embolization procedures. It eliminates a number of steps involved in using PVA in a vial,” said Jafar Golzarian, MD, Interventional Radiologist and Founder at Northstar Vascular and Interventional in Golden Valley, MN. “Unlike vial products, it’s ready to use, enabling interventional radiologists to focus on the procedure.”

As part of its commitment to innovation, education, and research in embolotherapy, Merit will participate in the 18th Annual Global Embolization Oncology Symposium Technologies (GEST) Meeting, to be held May 16-19, 2024, in New York City, NY. In addition to introducing the Siege Vascular Plug and Bearing nsPVA Express, Merit will be exhibiting other embolic product solutions, including Embosphere® Microspheres, EmboCube™ Embolization Gelatin, and Torpedo™ Gelatin Foam. Merit will also feature the SwiftNINJA® Steerable Microcatheter and the longer-length Merit Maestro® Microcatheter; both delivery systems are ideal for radial procedures.

Physicians can try these products through hands-on workshops held at the Merit booth. GEST attendees will also have access to Merit’s simulator for added prostatic artery embolization and uterine fibroid embolization experience involving Embosphere Microspheres and other Merit devices.

“Merit is a leader in embolotherapy,” said Fred P. Lampropoulos, Merit Chairman and Chief Executive Officer. “Through continued investment in new product solutions, we have developed a strong record of delivering meaningful innovation, new indications, and portfolio extensions designed to meet the needs of our healthcare partners. We look forward to demonstrating this excellence at GEST, showcasing the ways we help physicians deliver a better patient experience.”

ABOUT MERIT MEDICAL

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling over 700 individuals. Merit employs approximately 7,000 people worldwide.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

CONTACTS 

PR/Media Inquiries 

Sarah Comstock 

Merit Medical 

|  

INVESTOR INQUIRIES 

Mike Piccinino, CFA, IRC 

Westwicke - ICR 

| 

1. Data on File.

 



EN
14/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

 PRESS RELEASE

Merit Medical Reports Fourth Quarter and Full Year 2025 Results and Is...

Merit Medical Reports Fourth Quarter and Full Year 2025 Results and Issues Fiscal Year 2026 Guidance Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11%Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectivelyGAAP operating margin of 13.8%, compared to 10.3% in prior year periodNon-GAAP operating margin* of 21.0%, compared to 19.6% in prior year periodGAAP EPS $0.63, up 37%Non-GAAP EPS* $1.04, up 12%Free cash flow* generation of $74.0 million, up 13% Fiscal Year 2025 Highlights† Reported revenue of $1.516 billion, up 12%Constant c...

 PRESS RELEASE

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announ...

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025 SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit’s Lead Independent Director, as Chair of the Board effective January 5, 2026. Dr. Millner has served as a director of Merit since 2015 and as the Lead Independent Director since July 2021. She prev...

 PRESS RELEASE

Merit Medical to Participate at the J.P. Morgan Healthcare Conference

Merit Medical to Participate at the J.P. Morgan Healthcare Conference SOUTH JORDAN, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the 44th Annual J.P. Morgan Healthcare Conference, which is being held at The Westin St. Francis Hotel in San Francisco, California, January 12-15, 2026. To learn more, visit  Martha G. Aronson, President and Chief Executive Officer, and Raul Parra, Chief Financial Officer, will present a company overview and update on Tuesday, Ja...

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 88.038USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Merit Medical Provides Update on U.S. Reimbursement and Commercial Str...

Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“CMS”) has notified Merit that its application for Transitional Pass-Through (“TPT”) incremental payment for WRAPSODY® Cell-Impermeable Endoprosthesis (“CIE”) procedures in the outpatient and ambulatory surgery center (“ASC”) settings requires further conside...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch